Berry Genomics Co.,Ltd (SHE:000710)
China
· Delayed Price · Currency is CNY 14.29
+0.33 (2.36%)
May 14, 2025, 2:45 PM CST
Berry Genomics Co.,Ltd Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 1,078 | 1,129 | 1,343 | 1,370 | 1,504 | Upgrade
|
| Other Revenue | - | 21.92 | 24.64 | 52.43 | 36.1 | Upgrade
|
| Revenue | 1,078 | 1,151 | 1,368 | 1,422 | 1,540 | Upgrade
|
| Revenue Growth (YoY) | -6.36% | -15.83% | -3.81% | -7.67% | -4.78% | Upgrade
|
| Cost of Revenue | 572.91 | 668.26 | 821.85 | 827.75 | 760.94 | Upgrade
|
| Gross Profit | 505.26 | 483.16 | 546.15 | 594.43 | 779.45 | Upgrade
|
| Selling, General & Admin | 385.55 | 404.55 | 463.21 | 456.17 | 403.15 | Upgrade
|
| Research & Development | 95.42 | 110.01 | 106.74 | 128.23 | 125.8 | Upgrade
|
| Other Operating Expenses | 9.52 | 4.67 | 3.76 | 2.84 | 0.31 | Upgrade
|
| Operating Expenses | 490.49 | 681.99 | 671.71 | 640.85 | 560.85 | Upgrade
|
| Operating Income | 14.76 | -198.84 | -125.56 | -46.41 | 218.6 | Upgrade
|
| Interest Expense | - | -16.35 | -17.64 | -20.3 | -15.34 | Upgrade
|
| Interest & Investment Income | - | 2.64 | 2.36 | 5.05 | 44.05 | Upgrade
|
| Earnings From Equity Investments | -14.55 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.55 | -1.62 | 0.38 | -1.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -144.5 | -0.37 | 2.79 | -5.26 | -7.34 | Upgrade
|
| EBT Excluding Unusual Items | -144.29 | -213.47 | -139.66 | -66.54 | 238.88 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.13 | -82.67 | -144.31 | -49.13 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.74 | -0.01 | -0.35 | 0.26 | -0.45 | Upgrade
|
| Asset Writedown | -28.08 | -159.38 | -0.07 | -5.16 | -0.02 | Upgrade
|
| Other Unusual Items | - | 2.11 | 8.02 | 0.19 | 6.93 | Upgrade
|
| Pretax Income | -170.76 | -453.42 | -276.37 | -120.38 | 245.34 | Upgrade
|
| Income Tax Expense | 17.42 | -28.16 | -29.98 | -10.52 | 39.65 | Upgrade
|
| Earnings From Continuing Operations | -188.18 | -425.27 | -246.4 | -109.86 | 205.69 | Upgrade
|
| Minority Interest in Earnings | -4.25 | -1.93 | -2.53 | -0.96 | 4.97 | Upgrade
|
| Net Income | -192.43 | -427.2 | -248.93 | -110.82 | 210.67 | Upgrade
|
| Net Income to Common | -192.43 | -427.2 | -248.93 | -110.82 | 210.67 | Upgrade
|
| Net Income Growth | - | - | - | - | -46.07% | Upgrade
|
| Shares Outstanding (Basic) | 354 | 353 | 307 | 357 | 357 | Upgrade
|
| Shares Outstanding (Diluted) | 354 | 353 | 307 | 357 | 357 | Upgrade
|
| Shares Change (YoY) | 0.14% | 14.88% | -14.03% | 0.12% | 0.55% | Upgrade
|
| EPS (Basic) | -0.54 | -1.21 | -0.81 | -0.31 | 0.59 | Upgrade
|
| EPS (Diluted) | -0.54 | -1.21 | -0.81 | -0.31 | 0.59 | Upgrade
|
| EPS Growth | - | - | - | - | -46.36% | Upgrade
|
| Free Cash Flow | 31.22 | 55.91 | -52.13 | -242.66 | 48.76 | Upgrade
|
| Free Cash Flow Per Share | 0.09 | 0.16 | -0.17 | -0.68 | 0.14 | Upgrade
|
| Gross Margin | 46.86% | 41.96% | 39.92% | 41.80% | 50.60% | Upgrade
|
| Operating Margin | 1.37% | -17.27% | -9.18% | -3.26% | 14.19% | Upgrade
|
| Profit Margin | -17.85% | -37.10% | -18.20% | -7.79% | 13.68% | Upgrade
|
| Free Cash Flow Margin | 2.90% | 4.86% | -3.81% | -17.06% | 3.17% | Upgrade
|
| EBITDA | 91.95 | -98.87 | -33.42 | 50.94 | 295.5 | Upgrade
|
| EBITDA Margin | 8.53% | -8.59% | -2.44% | 3.58% | 19.18% | Upgrade
|
| D&A For EBITDA | 77.19 | 99.97 | 92.13 | 97.35 | 76.9 | Upgrade
|
| EBIT | 14.76 | -198.84 | -125.56 | -46.41 | 218.6 | Upgrade
|
| EBIT Margin | 1.37% | -17.27% | -9.18% | -3.26% | 14.19% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 16.16% | Upgrade
|
| Revenue as Reported | - | 1,151 | 1,368 | 1,422 | 1,540 | Upgrade
|
Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.